Scientist in front of whiteboard
Next-Generation Sequencing

Maximize insights with multimodal sequencing

Why choose QIAseq Multimodal technology?

Recent advances in NGS and bioinformatics have empowered researchers to efficiently interrogate DNA and RNA modifications in biological samples. However, current approaches require two separate workflows for DNA and RNA library preparation, each with inherent bias. Having different workflows increases costs and turnaround times, ultimately delaying the acquisition of actionable data. Limited sample availability can also impact your ability to achieve comprehensive genomic and transcriptomic insights.

One sample, one workflow and one day is all you need

Maximize the information you derive from a single total nucleic acid sample by simultaneously profiling DNA and RNA biomarkers in one consolidated workflow and just one day. With QIAseq Multimodal technology, you can interrogate various biomarkers in the same, single-day workflow from as little as 10 ng of sample.

Unlock DNA and RNA biomarker insights simultaneously
Explore how QIAseq Multimodal technology can save you valuable resources and time – discuss your project needs with us.
Applying multimodal sequencing technology to profile solid tumors
Dr. Barnaby Clark, Laboratory Lead for Precision Medicine at Kings College Hospital NHS Foundation Trust, discusses how QIAseq multimodal sequencing technology reduces his overall turnaround times for processing solid tumor samples due to simultaneous DNA and RNA library prep and automation.
Dr. Vincent Funari
“QIAseq Multimodal Panels are a cutting-edge method that allowed us to simultaneously identify DNA variants and RNA fusions for comprehensive profiling of tumors.”

Dr. Vincent Funari, Vice President of Research and Development at NeoGenomics Laboratories

 

Go from sample to sequencing in a day
Need further information?
Explore performance data and more in our downloadable resources!
Target regions of interest with custom panels

Incorporate the benefits of QIAseq Multimodal technology and design your own panels. With our custom designs, you can target exonic regions of genes, hotspots or SNPs, intronic and promoter regions, known gene fusions based on characterized breakpoints and even discover novel fusions.

QIAseq Multimodal
Have a question about custom design?
Our specialists are ready to help you.

Comprehensive genomic profiling (CGP) is dramatically changing our understanding of various cancers, revealing an unprecedented level of detail. Multimodal sequencing can accelerate this rapidly evolving field of research.

Top 3 reasons to adopt a multimodal approach for CGP:

  1. Save time and resources: Consolidate separate workflows into a single-day, sample to sequencing workflow.
  2. Conserve precious samples: Simultaneously profile multiple DNA and RNA biomarkers, TMB and MSI from a single, low-input sample.
  3. Get deeper insights: Achieve a holistic view of various cancer biomarkers efficiently.
QIAseq Multimodal
Unlock insights into multiple cancers with just 10 ng total nucleic acid input

The QIAseq Pan-cancer Multimodal Panel enables simultaneous enrichment and profiling of 605 relevant DNA variant and RNA fusion biomarkers found across multiple cancers, as well as assessment of tumor mutational burden (TMB) and microsatellite instability (MSI), from a single sample input of 10 ng.

Ask our experts about comprehensive genomic profiling
Explore how QIAseq Multimodal technology can transfrom your cancer research.
What can you profile with the QIAseq Pan-cancer Multimodal Panel?

Explore the QIAseq Pan-cancer Multimodal Panel

Cover 523 DNA gene targets, 56 RNA fusion targets and 26 MSI loci.
Take the shortcut – library normalization without quantification

Save time and ditch that traditional time-consuming library quantification method. With our QIAseq Normalizer Kit, you can easily pool libraries without the need for library quantification and still achieve qPCR-level accuracy. All it takes is 30 min.

Normalizer illustration main header
  • Evolution of tumor profiling in a clinical lab: Moving toward comprehensive genomic profiling
    In this webinar, Vincent Funari of NeoGenomics will discuss how his team has evolved its profiling approaches for both heme and solid tumors from targeted panels to more comprehensive genomic profiling.
    Two young scientist having a webinar
  • Comprehensive genomic profiling of solid tumors and heme malignancies
    In this webinar, we discuss how you can uncover insights into multiple cancers from just 1 ng total nucleic acid using the QIAseq Pan-cancer Multimodal Panel. Learn about the technology and how it can ensure superior coverage while saving time and costs.
    generic webinar image, male person sitting in an office watching a webinar, labtop, screen, work on comuter
  • One-day workflow for simultaneous profiling of DNA variants and RNA fusions
    In this webinar, we explore a new workflow for simultaneous NGS profiling of both DNA variants and RNA fusions, as well as gene expression in just one day, using as little as 10 ng sample.
    QIAseq Multimodal
  • Analyzing multimodal data with QIAGEN CLC Genomics Workbench
    In this webinar, we will take you through an introduction and live demo of the QIAGEN CLC Genomics Workbench workflow for multimodal analysis. Discover this intuitive yet powerful solution tailored for analysis of NGS data generated with QIAseq Multimodal Panels.
    Bioinformatics
  • Two young scientist having a webinar
    Evolution of tumor profiling in a clinical lab: Moving toward comprehensive genomic profiling
  • generic webinar image, male person sitting in an office watching a webinar, labtop, screen, work on comuter
    Comprehensive genomic profiling of solid tumors and heme malignancies
  • QIAseq Multimodal
    One-day workflow for simultaneous profiling of DNA variants and RNA fusions
  • Bioinformatics
    Analyzing multimodal data with QIAGEN CLC Genomics Workbench
Automate and accelerate your library prep
How can automating your NGS library prep benefit your lab?
All photos taken prior to COVID-19